CM
Crestline Management Portfolio holdings
AUM
$62.6M
This Quarter Return
+31.46%
1 Year Return
-18.06%
3 Year Return
+16.7%
5 Year Return
+67.08%
10 Year Return
+99.86%
AUM
$719M
AUM Growth
+$719M
(-3.5%)
Cap. Flow
-$293M
Cap. Flow
% of AUM
-40.7%
Top 10 Holdings %
Top 10 Hldgs %
66.29%
Holding
200
New
72
Increased
18
Reduced
27
Closed
77
Top Buys
| 1 |
FNB Corp
FNB
|
$8M |
| 2 |
Travelers Companies
TRV
|
$7.78M |
| 3 |
Sherwin-Williams
SHW
|
$7.34M |
| 4 |
Willis Towers Watson
WTW
|
$5.75M |
| 5 |
Allstate
ALL
|
$5.64M |
Top Sells
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$360M |
| 2 |
Celanese
CE
|
$6.41M |
| 3 |
MON
Monsanto Co
MON
|
$6.27M |
| 4 |
Bunge Global
BG
|
$5.97M |
| 5 |
Air Products & Chemicals
APD
|
$4.65M |
Sector Composition
| 1 | Financials | 19.98% |
| 2 | Industrials | 5.93% |
| 3 | Healthcare | 5.67% |
| 4 | Technology | 4.78% |
| 5 | Communication Services | 1.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Cadence Bank
CADE
$6.97B
| $962K | 0.13% |
30,000
-5,000
| -14% | -$160K |
|
102
PTC Therapeutics
PTCT
$4.41B
| $955K | 0.13% |
47,718
-50,071
| -51% | -$1M |
|
|
STML
103
DELISTED
Stemline Therapeutics, Inc.
STML
| $935K | 0.13% |
84,210
+104
| +0.1% | +$1.16K |
|
|
COUP
104
DELISTED
Coupa Software Incorporated
COUP
| $909K | 0.13% |
+29,184
| New | +$909K |
|
105
KALA BIO
KALA
$105M
| $888K | 0.12% |
+778
| New | +$888K |
|
106
FTI Consulting
FCN
$5.43B
| $863K | 0.12% |
+24,318
| New | +$863K |
|
|
CBAY
107
DELISTED
Cymabay Therapeutics
CBAY
| $841K | 0.12% |
+104,392
| New | +$841K |
|
108
Rigel Pharmaceuticals
RIGL
$710M
| $836K | 0.12% |
32,904
-14,265
| -30% | -$362K |
|
109
CNO Financial Group
CNO
$3.86B
| $797K | 0.11% |
34,151
| – | – |
|
110
First American
FAF
$6.63B
| $797K | 0.11% |
+15,954
| New | +$797K |
|
111
Amicus Therapeutics
FOLD
$2.42B
| $797K | 0.11% |
+52,845
| New | +$797K |
|
112
Ardelyx
ARDX
$1.57B
| $790K | 0.11% |
141,066
-70,661
| -33% | -$396K |
|
|
ARRY
113
DELISTED
Array Biopharma Inc
ARRY
| $729K | 0.1% |
+59,291
| New | +$729K |
|
114
AXIS Capital
AXS
$7.68B
| $703K | 0.1% |
+12,268
| New | +$703K |
|
115
SS&C Technologies
SSNC
$21.3B
| $673K | 0.09% |
+16,751
| New | +$673K |
|
116
Heron Therapeutics
HRTX
$204M
| $647K | 0.09% |
40,078
+3,058
| +8% | +$49.4K |
|
117
Syndax Pharmaceuticals
SNDX
$1.39B
| $626K | 0.09% |
53,532
-1,836
| -3% | -$21.5K |
|
118
Catalyst Pharmaceutical
CPRX
$2.42B
| $562K | 0.08% |
+223,019
| New | +$562K |
|
|
GHL
119
DELISTED
Greenhill & Co., Inc.
GHL
| $534K | 0.07% |
+32,178
| New | +$534K |
|
120
Fate Therapeutics
FATE
$115M
| $96K | 0.01% |
+24,174
| New | +$96K |
|
121
Valvoline
VVV
$4.88B
| – | – |
-51,250
| Closed | -$1.22M |
|
|
TTPH
122
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| – | – |
-8,070
| Closed | -$1.15M |
|
|
PTLA
123
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-18,305
| Closed | -$1.03M |
|
|
DERM
124
DELISTED
Dermira, Inc.
DERM
| – | – |
-19,917
| Closed | -$580K |
|
125
Manitowoc
MTW
$351M
| – | – |
-24,986
| Closed | -$601K |
|